Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Funding Amount Is In Question Until Tax Cut Resolved - Wilensky

Executive Summary

The amount of money left to fund a Medicare prescription drug benefit is a question that will not be answered until the size of the proposed tax cut is resolved, former Bush campaign advisor Gail Wilensky, PhD, indicated Feb. 1.

You may also be interested in...



Rx Reimportation Push Resumes: Gutknecht Sees Open Borders As Inevitable

Personal importation of prescription drugs will inevitably lead to reimportation at the wholesale level, Rep. Gutknecht (R-Minn.) suggested at a Washington, D.C., press conference Jan. 31.

Rx tax deductions

Restoration of federal tax deductions for out-of-pocket pharmaceutical expenses is among the top legislative priorities for the National Community Pharmacists Association in the 107th Congress. A Jan. 19 letter from NCPA to drug manufacturers asks them to support introduction of a "Consumer Medicine Tax Relief Act," which would provide "first-dollar deductibility of prescription drugs, OTC drugs, and pharmacist professional services under the federal tax code." NCPA is pushing the tax measure because it believes "a vigorous debate on tax reform" is likely to come before debate on Medicare reform

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS037298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel